Physician profile

Jonathan Miller

Medical · Boise, ID

NPI 1376570440

$313.01

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$116.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genzyme Corporation $77.55 2022-2023
Optinose US, INC. $66.75 2022-2023
Sanofi-Aventis U.S. LLC $56.95 2022
Regeneron Healthcare Solutions, INC. $31.84 2022-2023 Dupixent
Glaxosmithkline, LLC. $26.64 2023 Nucala
Stryker Corporation $19.23 2022
Inspire Medical Systems, INC. $17.40 2024 Inspire
Smith+Nephew, INC. $16.65 2023 Tula, Halo

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan Miller

$313.01

in general payments reported 2019-2025

Years
2022-2024
Top company
Genzyme Corporation

https://glasscript.com/doctor/10588270/jonathan-miller

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.